Defining ‘Surveillance’ in Drug Safety Jeffrey K. AronsonManfred HaubenAndrew Bate Leading Article 13 December 2012 Pages: 347 - 357
A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation Kate HutchinsonKelly CruickshankKevan Wylie Review Article 13 December 2012 Pages: 359 - 372
Impact of Safety-Related Regulatory Action on Clinical Practice Sigrid PieningFlora M. Haaijer-RuskampPeter G. M. Mol Systematic Review 13 December 2012 Pages: 373 - 385
Promoting Spontaneous Adverse Drug Reaction Reporting in Hospitals Using a Hyperlink to the Online Reporting Form Inês Ribeiro-VazCristina SantosRicardo Cruz-Correia Short Communication 13 December 2012 Pages: 387 - 394
A Pharmacoepidemiological Network Model for Drug Safety Surveillance Ben Y. ReisKaren L. OlsonKenneth D. Mandl Original Research Article 13 December 2012 Pages: 395 - 406
Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples Peter M. WahlJoshua J. GagneRhonda L. Bohn Original Research Article 13 December 2012 Pages: 407 - 416
A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals Hans C. EbbersAukje K. Mantel-TeeuwisseHubert G. M. Leufkens Original Research Article 13 December 2012 Pages: 417 - 427